Drug Profile
Topiramate - Janssen
Alternative Names: Epitomax; KW-6485; KW-6485P; MCN 4853; RWJ 17021; Topamax; Topamax Migraine; Topimax; Topina; Topina fine granulesLatest Information Update: 06 Dec 2023
Price :
$50
*
At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development
- Developer Janssen Inc; Janssen Research & Development; Janssen-Cilag; Johnson & Johnson Pharmaceutical Research & Development; Johnson & Johnson Pharmaceutical Research & Development LLC; Kyowa Kirin; Ortho-McNeil; Xian-Janssen
- Class Antiepileptic drugs; Antimigraines; Dioxolanes; Hexoses; Ketoses; Neuroprotectants; Obesity therapies; Pyrans; Small molecules; Sulfonic acids
- Mechanism of Action AMPA receptor antagonists; Carbonic anhydrase inhibitors; GABA A receptor agonists; GABA-A receptor antagonists; Kainic acid receptor antagonists; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Epilepsy; Lennox-Gastaut syndrome; Migraine
- No development reported Obesity; Post-traumatic stress disorders
- Discontinued Bipolar disorders; Diabetic neuropathies